alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–25 of 27 studies in The Journal of clinical psychiatry (page 1 of 2) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia

✓ Peer-reviewed alzhub usefulness score 68 out of 100. The Journal of clinical psychiatry 2003-02-01

The trial was completed by 67% of patients in the placebo group and 73% of patients in the risperidone group. 3 key findings →

Participants: 345 Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group

✓ Peer-reviewed alzhub usefulness score 68 out of 100. The Journal of clinical psychiatry 1999-02-01

The study was completed by 70% of the patients. 4 key findings →

Participants: 625 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study

✓ Peer-reviewed alzhub usefulness score 66 out of 100. The Journal of clinical psychiatry 2009-06-01

The current results do not support the notion that lithium treatment may lead to reduced hyperphosphorylation of tau protein after a short 10-week treatment in the Alzheimer's disease target population. 2 key findings →

Participants: 38 Evidence: low

Full summary, score breakdown and related studies → Original source

Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry

✓ Peer-reviewed alzhub usefulness score 65 out of 100. The Journal of clinical psychiatry 2006-12-01

The preponderance of epidemiologic and tissue compositional studies supports a protective effect of omega-3 EFA intake, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), in mood disorders. 3 key findings →

Design: meta-analysis Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

A randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients

✓ Peer-reviewed alzhub usefulness score 61 out of 100. The Journal of clinical psychiatry 2005-02-01

This randomized, observer-blind, controlled trial examined the efficacy and safety of the traditional Chinese herbal medicine Yi-Gan San (YGS, Yokukan-San in Japanese) in the improvement of behavioral and psychological symptoms of dementia (BPSD) and activities of daily living (ADL). 4 key findings →

Participants: 27 Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Effect of second-generation antipsychotics on caregiver burden in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 59 out of 100. The Journal of clinical psychiatry 2011-09-06

In AD patients with symptoms of psychosis, agitation, or aggressive behavior, medications can have a small but significant impact on caregiver burden. 4 key findings →

Design: clinical trial Participants: 361 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients

✓ Peer-reviewed alzhub usefulness score 59 out of 100. The Journal of clinical psychiatry 2009-04-21

The increase in gray matter volume in these areas, which various neuroimaging and postmortem neuropathology studies have implicated in the neuropathophysiology of bipolar disorder, suggests that the observed effects may be linked to clinical response. 5 key findings →

Design: longitudinal study Participants: 28 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume

✓ Peer-reviewed alzhub usefulness score 57 out of 100. The Journal of clinical psychiatry 2011-05-18

Biological changes activated by stress represent a significant factor influencing brain structure and function in first-episode psychosis through an effect on BDNF. 4 key findings →

Design: case-control study Participants: 19 Evidence: moderate

Full summary, score breakdown and related studies → Original source

The diagnostic challenge of psychiatric symptoms in neurodegenerative disease: rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease

✓ Peer-reviewed alzhub usefulness score 56 out of 100. The Journal of clinical psychiatry 2011-02-01

Depression was the most common psychiatric diagnosis in all groups. 2 key findings →

Participants: 69 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Hippocampal and amygdala changes in patients with major depressive disorder and healthy controls during a 1-year follow-up

✓ Peer-reviewed alzhub usefulness score 52 out of 100. The Journal of clinical psychiatry 2004-04-01

These results do not support the hypothesis that hippocampal volumes diminish during the 1-year follow-up period. 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source

Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy

✓ Peer-reviewed alzhub usefulness score 47 out of 100. The Journal of clinical psychiatry 2008-06-01

This article outlines methodological enhancements to better evaluate treatment approaches in future registration trials and provides an algorithm for improving the treatment of these patients in nursing home and non-nursing home settings. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Plasma NfL, P-tau181, and P-tau181/Aβ42 Ratio in Predicting Mild Behavioral Impairment in Dementia-Free Multiethnic Asian Older Adults With Mixed Pathology in a 5-Year Clinical Cohort

✓ Peer-reviewed alzhub usefulness score 44 out of 100. The Journal of clinical psychiatry 2025-03-05

The underlying mechanisms of mild behavioral impairment (MBI), a marker for cognitive impairment and dementia, have remained unclear especially in a multiethnic Asian population. 4 key findings →

Participants: 305 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 41 out of 100. The Journal of clinical psychiatry 2007-04-01

This study provides empirical support for the suggestion that the APOE locus is the major susceptibility gene for late-onset AD in the human genome, with an OR significantly greater than any other locus in the human genome. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Biology of posttraumatic stress disorder

✓ Peer-reviewed alzhub usefulness score 36 out of 100. The Journal of clinical psychiatry 2001-01-01

Most biological findings in posttraumatic stress disorder (PTSD) are compatible with those of the chronic stress response, such as increased corticotropin-releasing factor (CRF) concentrations, catecholamine depletion within the central nervous system, and reduced hippocampal volume. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed